Media
Latest News
May 5, 2020
When it comes to how and when to reopen the economy, it's not just governors, but national lawmakers, who aren't seeing eye-to-eye on how to toe the line between public safety and economic health.
Issues:Coronavirus (COVID-19)
May 4, 2020
Washington, D.C. – Today, U.S. Representative Lloyd Doggett (D-TX), Chairman of the House Ways and Means Health Subcommittee, led Members in urging Gilead CEO Daniel O’Day to detail the company’s plans for remdesivir, including securing and scaling up the supply chain, complete disclosures of taxpayer investment in the development of the drug, and purchase and pricing arrangements. As remdesivir—which has been developed with significant taxpayer investment—receives FDA emergency use authorization, the lawmakers questioned its affordability and accessibility for patients.
May 4, 2020
Washington, D.C. – As the COVID-19 pandemic places unique pressures on food supply chains in the United States, U.S. Representative Lloyd Doggett (D-TX), Chairman of the House Ways and Means Health Subcommittee, led Members in urging the Department of Agriculture to curb the extreme measures for “depopulation” at some animal slaughter facilities. Their letter raises concerns about mass suffocation of animals who are being quickly cleared from facilities and urges use of more humane practices.
May 4, 2020
Washington, D.C. – Following today’s Food and Drug Administration (FDA) announcement of changes in requirements for antibody tests, U.S. Representative Lloyd Doggett (D-TX), Chairman of the House Ways and Means Health Subcommittee, released the following statement:
Issues:Coronavirus (COVID-19)
May 4, 2020
The Food and Drug Administration announced on Monday that companies selling coronavirus antibody tests must submit data proving accuracy within the next 10 days or face removal from the market.
Issues:Coronavirus (COVID-19)
May 4, 2020
The Food and Drug Administration on Monday tightened rules for coronavirus antibody tests, ordering manufacturers to submit emergency use authorization forms and data proving the tests work within 10 days or face possible removal.
Issues:Coronavirus (COVID-19)
May 4, 2020
Gilead Sciences Inc. plans to spend $1 billion on its Covid-19 drug remdesivir. Now some members of Congress and health care watchdogs want to know how much consumers will pay.
Issues:Coronavirus (COVID-19)
May 3, 2020
President Donald Trump has been following up with the millions of Americans who received economic stimulus checks, touting the legislation that provided the financial relief and promising that America will prevail over an “invisible enemy.”
Issues:Coronavirus (COVID-19)
May 1, 2020
Washington, D.C. – Amid announcements concerning preliminary clinical trial data on remdesivir and anticipated emergency use authorization from the FDA, U.S. Representative Lloyd Doggett (D-TX), Chair of the House Ways and Means Health Subcommittee, and Rep. Rosa DeLauro (D-CT), Chair of the Labor, Health and Human Services, and Education Appropriations Subcommittee, urge Secretary Azar to release information about the extent of taxpayer investment in remdesivir, government ownership of any remdesivir patents, and any federal efforts to scale-up production. Arguing that an unaffordable drug is entirely ineffective for patients suffering, the members assert that “substantial taxpayer investments in COVID-19 pharmaceutical research must be recognized.”
Issues:Coronavirus (COVID-19)
May 1, 2020
An Austin-area veteran says Austin Community College sent him an email Thursday, telling him his GI Bill benefits were going to be slashed -- all because the school was listing summer school courses in a way that meant veterans wouldn't get the full housing benefit they earned. This comes as the school continues to offer online learning in response to the COVID-19 pandemic.